Clinical Trial: Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06824103) titled 'Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease' on Feb. 04.

Brief Summary: The purpose of the study is to assess the efficacy and safety of ruxolitinib in Chinese adult and pediatric participants aged 12 years or older with corticosteroid-refractory chronic graft vs. host disease (SR-cGvHD).

Study Start Date: Nov. 21, 2025

Study Type: INTERVENTIONAL

Condition: Graft vs. Host Disease Chronic Graft vs. Host Disease Corticosteroid-refractory Chronic Graft vs. Host Disease

Intervention: DRUG: Ruxolitinib

Ruxolitinib is taken orally daily at 10 mg B...